摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

2-羟基-2-甲基丁酸乙酯 | 77-70-3

中文名称
2-羟基-2-甲基丁酸乙酯
中文别名
——
英文名称
α-hydroxy-α-methylbutyric acid ethyl ester
英文别名
ethyl 2-hydroxy-2-methylbutanoate;2-hydroxy-2-methyl-butyric acid ethyl ester;2-Hydroxy-2-methyl-buttersaeure-aethylester;α-Oxy-α-methyl-buttersaeure-aethylester;Methylaethylglykolsaeure-aethylester;ethyl 2-hydroxy-2-methylbutyrate
2-羟基-2-甲基丁酸乙酯化学式
CAS
77-70-3
化学式
C7H14O3
mdl
MFCD00040217
分子量
146.186
InChiKey
KIYWRWLZHQZKKD-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    68-70 °C(Press: 25 Torr)
  • 密度:
    1.007±0.06 g/cm3(Predicted)
  • LogP:
    0.69
  • 物理描述:
    Clear, colourless liquid; Caramelised, nutty aroma
  • 溶解度:
    Sparingly soluble in water; soluble in most non-polar organic solvents
  • 折光率:
    1.409-1.416
  • 保留指数:
    902

计算性质

  • 辛醇/水分配系数(LogP):
    0.9
  • 重原子数:
    10
  • 可旋转键数:
    4
  • 环数:
    0.0
  • sp3杂化的碳原子比例:
    0.857
  • 拓扑面积:
    46.5
  • 氢给体数:
    1
  • 氢受体数:
    3

SDS

SDS:19811a78c6e64cf10ce42e282c5b39da
查看

反应信息

点击查看最新优质反应信息

文献信息

  • Mechanism and scope of salen bifunctional catalysts in asymmetric aldehyde and α-ketoester alkylation
    作者:Michael W. Fennie、Erin F. DiMauro、Erin M. O'Brien、Venkatachalam Annamalai、Marisa C. Kozlowski
    DOI:10.1016/j.tet.2005.03.117
    日期:2005.6
    complexes of C2-symmetric Lewis acid/Lewis base salen ligands provide bifunctional activation resulting in rapid rates in the enantioselective addition of diethylzinc to aldehydes (up to 92% ee). Further experiments probed the reactivity of the individual Lewis acid and Lewis base components of the catalyst and established that both moieties are essential for asymmetric catalysis. These catalysts are also
    C 2对称的路易斯酸/路易斯碱塞伦配体的金属配合物提供双功能激活,从而使二乙基锌对醛的对映选择性加成速率加快(最高ee为92%)。进一步的实验探查了催化剂中各个路易斯酸和路易斯碱组分的反应性,并确定这两个部分对于不对称催化都是必不可少的。这些催化剂在将二乙基锌不对称加成到α-酮酸酯中也是有效的。这一发现意义重大,因为单独的α-酮酸酯充当其自身的配体,以加速Et 2的外消旋1,2-羰基加成反应锌与外消旋羰基还原。后者通过金属茂途径进行,并且通常占主要产物。奇异的路易斯酸催化剂不能在这两个竞争路径上加速对映选择性的1,2-加成。然而,双官能氨基塞伦催化剂以优异的收率,完全的化学选择性和良好的对映选择性(高达88%ee)快速提供对映体富集的1,2-加成产物。合成了双功能氨基塞隆的文库,并在该反应中进行了评估。已经在鸦片拮抗剂的合成中证明了α-酮酸酯方法的实用性。
  • Development of Bifunctional Salen Catalysts:  Rapid, Chemoselective Alkylations of α-Ketoesters
    作者:Erin F. DiMauro、Marisa C. Kozlowski
    DOI:10.1021/ja026498h
    日期:2002.10.1
    which is a major coproduct with other catalysts, is not observed with these bifunctional salens. As a result, high yields of the addition products can be obtained (57−99%). Both the Lewis acid and Lewis base portions of the catalyst are critical to the reactivity and selectivity. The two separate portions of the catalyst have been shown to function in a cooperative manner.
    Lewis酸-Lewis碱salen配合物已被确定为将二烷基锌添加到α-酮酯中的高效催化剂。与醛或酮相比,二乙基锌和 α-酮酯之间的反应在没有催化剂的情况下是显着的。在催化剂的存在下,反应速率相对于背景增加了 100 多倍。此外,使用这些双功能Salens 没有观察到还原产物,它是其他催化剂的主要副产物。结果,可以获得高产率的加成产物(57-99%)。催化剂的路易斯酸和路易斯碱部分对反应性和选择性都至关重要。催化剂的两个独立部分已显示出协同作用。
  • BICYCLIC HETEROCYCLIC DERIVATIVE
    申请人:Nakahira Hiroyuki
    公开号:US20110190278A1
    公开(公告)日:2011-08-04
    The present invention relates to a compound of the following formula (I) or a pharmaceutically acceptable salt thereof, being useful as a renin inhibitor. [wherein R 1a is halogen, etc.; R 1m is H, etc.; G 1 is —N(R 1b )—, etc.; G 2 is —CO—, etc.; G 3 is —C(R 1c )(R 1d )—, etc.; G 4 is oxygen, etc.; R 1b is optionally substituted C 1-6 alkyl, etc.; R 1c and R 1d are independently the same or different, H, etc.; R 3 is H, optionally substituted C 1-6 alkyl, etc.; R 3a , R 3b , R 3 c and R 3d are independently the same or different, and a group: -A-B (said A is single bond, etc., and said B is H, etc.), etc.; and n is 1, etc.]
    本发明涉及以下式(I)的化合物或其药学上可接受的盐,其可用作肾素抑制剂。[其中,R1a是卤素等;R1m是H等;G1是—N(R1b)—等;G2是—CO—等;G3是—C(R1c)(R1d)—等;G4是氧等;R1b是可选取代的C1-6烷基等;R1c和R1d独立选择为H等;R3是H、可选取代的C1-6烷基等;R3a、R3b、R3c和R3d独立选择为相同或不同的基团:-A-B(其中A是单键等,B是H等)等;n为1等。]
  • INDOLIZINE INHIBITORS OF 5-LIPOXYGENASE
    申请人:Roppe Jeffrey Roger
    公开号:US20120214840A1
    公开(公告)日:2012-08-23
    Described herein are compounds and pharmaceutical compositions containing such compounds, which inhibit the activity of 5-lipoxygenase (5-LO). Also described herein are methods of using such 5-LO inhibitors, alone and in combination with other compounds, for treating respiratory, cardiovascular, and other leukotriene-dependent or leukotriene mediated conditions, diseases, or disorders.
    本文所述的是含有这些化合物的药物组合物,这些化合物抑制5-脂氧化酶(5-LO)的活性。本文还描述了使用这种5-LO抑制剂的方法,单独或与其他化合物联合使用,用于治疗呼吸系统、心血管系统和其他依赖或介导白三烯的情况、疾病或障碍。
  • Bicyclic heterocyclic derivative
    申请人:Nakahira Hiroyuki
    公开号:US08389511B2
    公开(公告)日:2013-03-05
    The present invention relates to a compound of the following formula (I) or a pharmaceutically acceptable salt thereof, being useful as a renin inhibitor. [wherein R1a is halogen, etc.; R1m is H, etc.; G1 is —N(R1b)—, etc.; G2 is —CO—, etc.; G3 is —C(R1c)(R1d)—, etc.; G4 is oxygen, etc.; R1b is optionally substituted C1-6 alkyl, etc.; R1c and R1d are independently the same or different, H, etc.; R3 is H, optionally substituted C1-6 alkyl, etc.; R3a, R3b, R3c and R3d are independently the same or different, and a group: -A-B (said A is single bond, etc., and said B is H, etc.), etc.; and n is 1, etc.]
    本发明涉及以下式(I)的化合物或其药学上可接受的盐,其作为肾素抑制剂有用。[其中R1a为卤素等;R1m为H等;G1为—N(R1b)—等;G2为—CO—等;G3为—C(R1c)(R1d)—等;G4为氧等;R1b为可选取代的C1-6烷基等;R1c和R1d独立且相同或不同,为H等;R3为H、可选取代的C1-6烷基等;R3a、R3b、R3c和R3d独立且相同或不同,为-A-B基团(其中A为单键等,B为H等)等;n为1等。]
查看更多